Wörns, Marcus-Alexander
Burns, Danielle
Paskow, Michael http://orcid.org/0000-0001-8850-9044
Makin, Harriet http://orcid.org/0000-0002-1769-2205
Miller, Jordan http://orcid.org/0000-0003-2068-5951
Turner, Lucy M.
Sah, Janvi http://orcid.org/0000-0002-7856-5947
Funding for this research was provided by:
AstraZeneca United States
Article History
Received: 14 March 2024
Accepted: 26 June 2024
First Online: 25 July 2024
Declarations
:
: Danielle Burns, Harriet Makin and Jordan Miller are current/previous employees and stockholders of Clarivate, a health economic and outcomes research consultancy that consults with various pharmaceutical and biotech companies and were paid consultants to AstraZeneca in connection with this study. Janvi Sah, Michael Paskow and Lucy M Turner are employees and shareholders at AstraZeneca. Marcus-Alexander Wörns has no conflict of interest to declare.
: This study was conducted in line with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Western-Copernicus Group (WCG) Institutional Review Board (IRB) on the 5 February 2022 (IRB study number: 1331769). This study is reported in accordance with the Standards for Reporting Qualitative Research (SRQR). The checklist is available as supplementary information (Supplementary Information ). Informed consent forms, signed by all participants, stated that data collected for this study would be submitted for publication. Informed consent was obtained from all individual participants included in the study.